Alpenglow Biosciences is an end-to-end 3D pathology platform that aims to accelerate drug development and improve clinical diagnostics.
Alpenglow Biosciences has raised $250K in total funding. The most recent round was Undisclosed. The last funding was announced in January 2026.
Alpenglow Biosciences's investors include Creative Destruction Lab, Dynamk Capital, National Institute of Health, Andy Hill Cancer Research Endowment (CARE) Fund, Mike Rice.
Alpenglow Biosciences is headquartered in Seattle, United States.
Alpenglow Biosciences is an end-to-end 3D pathology platform that aims to accelerate drug development and improve clinical diagnostics.
Alpenglow Biosciences is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alpenglow Biosciences — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/alpenglow-biosciences. Accessed September 30, 2026.
VCBacked. (2026). Alpenglow Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/alpenglow-biosciences
{{cite web |title=Alpenglow Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/alpenglow-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated